It would be really easy to fix this- you just have to alter the Fc-portion of the antibody. Of course, then all the prior trials would be moot.
Its an interesting thought but i don't see that as realistic. The cost of the company at this point is 10 million give or take, the reward for getting it at 5 million or 2 million is outweighed by the time lost in squabbling. It's better to suck up that extra 8 million, buy the company and then bring it to market.
Ok so here's a brief summary: The phase i trial had a number of patients (13%) who exhibited a lack of platelets, and one large question was whether this was a result of the platelet producing cells being affected by T-DM1. They found that the precursor to megakaryocyte differentiation was inhibited by T-dm1, and they claim it may be from the Fcy receptor (that binds the Fc fragment of T-DM1) because it required that receptor.
My take? I'm glad to see that this happens, because it is expected to happen. It's a negative side effect, but I always wondered how much this would happen. You put an antibody into a cell and it can bind and be internalized in one of two ways, through its Fc portion or through its Fab portion, and we are lucky that this is causing effects in only 13% of the patients. I'm not a physician, I'm a researcher so I don't know much about how bad exactly thrombocytopenia actually is, but it appears that this is not a reason to stop using the drug and it doesn't look like it will be a larger problem.
Sure, I'm just about to leave work and i should prob read the whole paper tonight and then post something later so we can discuss it. I spend enough time searching terms on this stupid company that it be nice to have more of a discussion about it.
Puma Biotechnology's ($PBYI) closely watched neratinib failed to beat out the blockbuster Herceptin in a mid-stage breast cancer trial, a miss the company said was no surprise as it touted success on a secondary goal.
seems to me that weakness in the IBB makes IMGN a good takedown target, so that the IBB weakness allows imgn to be run downward pretty quickly. I don't really think it's much more than a little profit taking, there hasn't been volume that is over the current 1.6 million average. Just an opportunity for someone to run the price down and flush some people out.
closer to the ask than the bid. I'd guess bought to open, it looks like the open interest for nov is steadily increasing in 400-1000 bunch lots of options.
One thing that concerns me greatly going into the next year is the distance that Roche is putting between itself and IMGN. It seems to have cut more of the ADCs that are IMGN-based and gone with more Seattle Genetics ones, and then its just given 100 million to another ADC company in southern san francisco. Why would they stop what appears to be a very productive collaboration (kadcyla) if there wasn't a good reason?
I wish the same thing, however it appears a major institution is exiting based on the constant selling, and after seeing kadcyla sales this morning i can see why: US growth has stalled. Europe is still growing, but its so small that it won't pass the 3% royalty structure. Roche negotiated well: by keeping both areas low, neither raises into the 4% or 5% tier.
im on fidelity and can't find this. I found the GMI report that ranks ECTE a 1. I don't think GMI has any insight into what ECTE is going through beyond what we know- we're mostly waiting for the PWC audit thingy to come back positive and not declare bankruptcy. I do think that if ECTE is upgraded by GMI etc then more people might flock to the stock, which would be a good thing.
God i hope you're right on this, i've been on the other side of this, where "buyout" has been held over the stock to keep longs invested while the price just trails down and down.
On the plus side, i actually think they will hit 100 million for the year in revenue, and that means that the price would correct hopefully. Their burn rate is close to 65 M annually, if i recall correctly, so that means they might be net positive for the year.
Its funny to hear that it is behaving this way because of a potential acquisition. If that were the case, there would be unexplained buying by people who have gotten a sniff of the rumor, not excessive selling. The truth is that probably one of the biggies has given up and is liquidating their position. On the bright side, it's probably only one, on the down side its screwed us all over.
IMGN is down particularly hard, like 7% at the peak today. I was thinking it was company specific- but it might be simply that they are crossing the 52 week low and there's stop losses triggered. I was purchasing at 9.86, just a small bit more.
Well that's not going to happen. Charlie Morris was just granted a house stipend- so these guys aren't going anywhere.
if echo just fired 70% of the workforce, leaving the three directors plus some of their friends, who is going to get paid with this money?